This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (575)

Published on in Vol 7, No 8 (2018): August

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/11003, first published .
Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel in Patients With Cis-Platinum–Intolerant Core High-Risk Head and Neck Cancer: Protocol of a Phase 2 Nonrandomized Clinical Trial

Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel in Patients With Cis-Platinum–Intolerant Core High-Risk Head and Neck Cancer: Protocol of a Phase 2 Nonrandomized Clinical Trial

Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel in Patients With Cis-Platinum–Intolerant Core High-Risk Head and Neck Cancer: Protocol of a Phase 2 Nonrandomized Clinical Trial

Authors of this article:

Goshi Nishimura1 Author Orcid Image ;   Hiromitsu Hatakeyama2 Author Orcid Image ;   Osamu Shiono3 Author Orcid Image ;   Masataka Taguri4 Author Orcid Image ;   Masanori Komatsu2 Author Orcid Image ;   Daisuke Sano1 Author Orcid Image ;   Naoko Sakuma2 Author Orcid Image ;   Kenichiro Yabuki1 Author Orcid Image ;   Yasuhiro Arai1 Author Orcid Image ;   Kunihiko Shibata2 Author Orcid Image ;   Yoshihiro Chiba1 Author Orcid Image ;   Teruhiko Tanabe1 Author Orcid Image ;   Nobuhiko Oridate1 Author Orcid Image
Article Authors Cited by (3) Tweetations (1) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.